{
    "organizations": [],
    "uuid": "db99c3cb7cee32088f33d239b058a77f16042635",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-lupin-signs-agreement-with-csir-nc/brief-lupin-signs-agreement-with-csir-ncl-and-dst-idUSFWN1QQ00U",
    "ord_in_thread": 0,
    "title": "BRIEF-Lupin Signs Agreement With CSIR-NCL And DST",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 8 (Reuters) - Lupin Ltd:\n* SIGNS AGREEMENT WITH CSIR-NCL AND DST FOR DEVELOPMENT OF CONTINUOUS MANUFACTURING PROCESS FOR BIOSIMILAR MONOCLONAL ANTIBODY THERAPEUTIC‍​ Source text: bit.ly/2tuFC1Q Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-03-08T13:31:00.000+02:00",
    "crawled": "2018-03-09T14:32:03.010+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "lupin",
        "ltd",
        "sign",
        "agreement",
        "dst",
        "development",
        "continuous",
        "manufacturing",
        "process",
        "biosimilar",
        "monoclonal",
        "antibody",
        "source",
        "text",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}